Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

basil insulin lispro

- PMLiVE

Merck & Co says Januvia follow-up looking good

Diabetes drug shows promise in phase II as once-weekly treatment

JDRF and Lilly take diabetes education to secondary schools

The partnership will use a new resource to teach students about type 1 diabetes

EMA recommends Lilly’s erectile dysfunction drug for enlarged prostate

Cialis would be first drug available in Europe for both ED and BPH

Novo Nordisk invests $100m in research in China

Expands existing site in Beijing

Novartis building

CHMP backs trio of Novartis products

Including two diabetes drugs and one for non-cancerous kidney tumours

Diabetes apps present usability problems for older adults

Researchers find a range of potential design problems with smartphone apps

- PMLiVE

Boehringer-Lilly tap into behavioural change for online diabetes programme

Part of the partners' Tradjenta marketing, My Well Planner offers personalised educational resources

- PMLiVE

Lilly’s poor run continues as Alimta fails in lung cancer

Phase III trial comparing it to Roche's Avastin misses primary endpoint

- PMLiVE

Lilly launches branded app for emergency diabetes medicine

US-only Lilly Glucagon iPhone and iPad app shows carers how to use the hypoglycaemia treatment

- PMLiVE

Lilly appoints Michael Harrington SVP and general counsel

Replaces Robert Armitage who retires from the pharma company

Lilly drops touted Zyprexa successor for use in schizophrenia

Pomaglumetad methionil disappoints in phase III

- PMLiVE

Lilly’s Alzheimer’s drug solanezumab stumbles, but doesn’t fall in phase III

Fails to show significant benefit, but data holds some consolation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links